Trial Information
Inclusion Criteria:
- Postmenopausal status
- Currently being treated with an AI in the adjuvant setting (minimum for 8 weeks)
- AIMSS as determined by new or worsened musculoskeletal complaints following AI
therapy
- Vitamin D deficiency (<30ng/ml)
- Caucasian
Exclusion Criteria:
-
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Outcome Measure:
Change from baseline in musculoskeletal pain and 250HD levels
Outcome Time Frame:
3 monthly during one year
Safety Issue:
No
Authority:
Belgium: Federal Agency for Medicines and Health Products, FAMHP
Study ID:
s55283
NCT ID:
NCT01809171
Start Date:
May 2013
Completion Date:
Related Keywords:
- Breast Cancer
- Musculoskeletal Disease
- Breast Neoplasms
- Musculoskeletal Diseases